Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
Identifieur interne : 000331 ( Ncbi/Curation ); précédent : 000330; suivant : 000332Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
Auteurs : Franklin M. Chu [États-Unis] ; Roger R. Dmochowski ; Daniel J. Lama ; Rodney U. Anderson ; Peter K. SandSource :
- American journal of obstetrics and gynecology [ 0002-9378 ] ; 2005.
English descriptors
- KwdEn :
- Benzhydryl Compounds (administration & dosage), Benzhydryl Compounds (adverse effects), Central Nervous System (drug effects), Cresols (administration & dosage), Cresols (adverse effects), Delayed-Action Preparations, Double-Blind Method, Female, Humans, Mandelic Acids (administration & dosage), Mandelic Acids (adverse effects), Muscarinic Antagonists (administration & dosage), Muscarinic Antagonists (adverse effects), Phenylpropanolamine (administration & dosage), Phenylpropanolamine (adverse effects), Randomized Controlled Trials as Topic, Tolterodine Tartrate, Urinary Incontinence (drug therapy), Urinary Incontinence (physiopathology).
- MESH :
- chemical , administration & dosage : Benzhydryl Compounds, Cresols, Mandelic Acids, Muscarinic Antagonists, Phenylpropanolamine.
- chemical , adverse effects : Benzhydryl Compounds, Cresols, Mandelic Acids, Muscarinic Antagonists, Phenylpropanolamine.
- drug effects : Central Nervous System.
- drug therapy : Urinary Incontinence.
- physiopathology : Urinary Incontinence.
- chemical : Delayed-Action Preparations, Double-Blind Method, Female, Humans, Randomized Controlled Trials as Topic, Tolterodine Tartrate.
Abstract
This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial.
DOI: 10.1016/j.ajog.2005.03.036
PubMed: 15970828
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000523
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000523
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000498
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000331
Links to Exploration step
pubmed:15970828Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.</title><author><name sortKey="Chu, Franklin M" sort="Chu, Franklin M" uniqKey="Chu F" first="Franklin M" last="Chu">Franklin M. Chu</name><affiliation wicri:level="2"><nlm:affiliation>San Bernardino Urological Associates, CA 92404, USA. FMCSBU@aol.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>San Bernardino Urological Associates, CA 92404</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dmochowski, Roger R" sort="Dmochowski, Roger R" uniqKey="Dmochowski R" first="Roger R" last="Dmochowski">Roger R. Dmochowski</name></author><author><name sortKey="Lama, Daniel J" sort="Lama, Daniel J" uniqKey="Lama D" first="Daniel J" last="Lama">Daniel J. Lama</name></author><author><name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U" last="Anderson">Rodney U. Anderson</name></author><author><name sortKey="Sand, Peter K" sort="Sand, Peter K" uniqKey="Sand P" first="Peter K" last="Sand">Peter K. Sand</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1016/j.ajog.2005.03.036</idno><idno type="RBID">pubmed:15970828</idno><idno type="pmid">15970828</idno><idno type="wicri:Area/PubMed/Corpus">000523</idno><idno type="wicri:Area/PubMed/Curation">000523</idno><idno type="wicri:Area/PubMed/Checkpoint">000498</idno><idno type="wicri:Area/Ncbi/Merge">000331</idno><idno type="wicri:Area/Ncbi/Curation">000331</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.</title><author><name sortKey="Chu, Franklin M" sort="Chu, Franklin M" uniqKey="Chu F" first="Franklin M" last="Chu">Franklin M. Chu</name><affiliation wicri:level="2"><nlm:affiliation>San Bernardino Urological Associates, CA 92404, USA. FMCSBU@aol.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>San Bernardino Urological Associates, CA 92404</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dmochowski, Roger R" sort="Dmochowski, Roger R" uniqKey="Dmochowski R" first="Roger R" last="Dmochowski">Roger R. Dmochowski</name></author><author><name sortKey="Lama, Daniel J" sort="Lama, Daniel J" uniqKey="Lama D" first="Daniel J" last="Lama">Daniel J. Lama</name></author><author><name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U" last="Anderson">Rodney U. Anderson</name></author><author><name sortKey="Sand, Peter K" sort="Sand, Peter K" uniqKey="Sand P" first="Peter K" last="Sand">Peter K. Sand</name></author></analytic><series><title level="j">American journal of obstetrics and gynecology</title><idno type="ISSN">0002-9378</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benzhydryl Compounds (administration & dosage)</term><term>Benzhydryl Compounds (adverse effects)</term><term>Central Nervous System (drug effects)</term><term>Cresols (administration & dosage)</term><term>Cresols (adverse effects)</term><term>Delayed-Action Preparations</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Mandelic Acids (administration & dosage)</term><term>Mandelic Acids (adverse effects)</term><term>Muscarinic Antagonists (administration & dosage)</term><term>Muscarinic Antagonists (adverse effects)</term><term>Phenylpropanolamine (administration & dosage)</term><term>Phenylpropanolamine (adverse effects)</term><term>Randomized Controlled Trials as Topic</term><term>Tolterodine Tartrate</term><term>Urinary Incontinence (drug therapy)</term><term>Urinary Incontinence (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Benzhydryl Compounds</term><term>Cresols</term><term>Mandelic Acids</term><term>Muscarinic Antagonists</term><term>Phenylpropanolamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Benzhydryl Compounds</term><term>Cresols</term><term>Mandelic Acids</term><term>Muscarinic Antagonists</term><term>Phenylpropanolamine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Central Nervous System</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Urinary Incontinence</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Urinary Incontinence</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Delayed-Action Preparations</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Tolterodine Tartrate</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000331 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000331 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:15970828
|texte= Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:15970828" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |